This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovasculardisease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J.
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovasculardisease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J.
Hashtag: #HeartFailure2025 European Atherosclerosis Society (EAS) Congress 2025 Date: May 4-7, 2025 Location: Glasgow, UK and online Overview: The European Atherosclerosis Society (EAS) and the British Atherosclerosis Society (BAS) will be hosting the 93 rd EAS Congress, to be held in the city of Lyon.
Circulation: CardiovascularImaging, Ahead of Print. It is well understood that cancer therapies including chemotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors, and radiation can increase the risk of cardiovasculardisease in patients with cancer.
Presence of atherosclerosis with LDL-C and HBA1c in the ‘normal range’ What the above graph shows is that for those with an LDL-C of 3.4 mmol/l (130 mg/dl) or below, between 20-50% will already have coronary artery disease. 4 Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week.
Circulation: CardiovascularImaging, Ahead of Print. BACKGROUND:Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying the effect of lipid-lowering therapy on disease regression remain poorly characterized.
Circulation: CardiovascularImaging, Volume 17, Issue 2 , Page e015712, February 1, 2024. BACKGROUND:Coronary artery calcium computed tomography (CAC) is an important tool for identifying subclinical atherosclerosis and cardiovascular risk stratification.
Circulation: CardiovascularImaging, Ahead of Print. BACKGROUND:Immune checkpoint inhibitors (ICIs), though revolutionary in cancer treatment, may accelerate atherosclerosis by inducing arterial inflammation. In ICI users, [18F]FDG uptake increased by 2.5% annually (95% CI, 1.7%3.3%;P=0.001 P=0.001 for interaction with no ICI).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content